148 related articles for article (PubMed ID: 9167082)
21. A hybrid machine learning/pharmacokinetic approach outperforms maximum a posteriori Bayesian estimation by selectively flattening model priors.
Hughes JH; Keizer RJ
CPT Pharmacometrics Syst Pharmacol; 2021 Oct; 10(10):1150-1160. PubMed ID: 34270885
[TBL] [Abstract][Full Text] [Related]
22. Reduction of a Whole-Body Physiologically Based Pharmacokinetic Model to Stabilise the Bayesian Analysis of Clinical Data.
Wendling T; Tsamandouras N; Dumitras S; Pigeolet E; Ogungbenro K; Aarons L
AAPS J; 2016 Jan; 18(1):196-209. PubMed ID: 26538125
[TBL] [Abstract][Full Text] [Related]
23. A Metropolis Monte Carlo implementation of bayesian time-domain parameter estimation: application to coupling constant estimation from antiphase multiplets.
Andrec M; Prestegard JH
J Magn Reson; 1998 Feb; 130(2):217-32. PubMed ID: 9500892
[TBL] [Abstract][Full Text] [Related]
24. [Estimation of individual pharmacokinetic parameters using maximum a posteriori Bayesian method with D-optimal sampling strategy].
Ding JJ; Jiao Z; Wang Y
Yao Xue Xue Bao; 2011 Dec; 46(12):1493-500. PubMed ID: 22375425
[TBL] [Abstract][Full Text] [Related]
25. More stable estimation of the STARTS model: A Bayesian approach using Markov chain Monte Carlo techniques.
Lüdtke O; Robitzsch A; Wagner J
Psychol Methods; 2018 Sep; 23(3):570-593. PubMed ID: 29172612
[TBL] [Abstract][Full Text] [Related]
26. Bayesian estimation of pharmacokinetic parameters for DCE-MRI with a robust treatment of enhancement onset time.
Orton MR; Collins DJ; Walker-Samuel S; d'Arcy JA; Hawkes DJ; Atkinson D; Leach MO
Phys Med Biol; 2007 May; 52(9):2393-408. PubMed ID: 17440242
[TBL] [Abstract][Full Text] [Related]
27. [Can we use a Bayesian method to build a pharmacokinetic population in two steps?].
Cabelguenne D; Bleyzac N; Pivot C; Maire P
Therapie; 2000; 55(2):277-82. PubMed ID: 10967700
[TBL] [Abstract][Full Text] [Related]
28. Developing population pharmacokinetic parameters for high-dose methotrexate therapy: implication of correlations among developed parameters for individual parameter estimation using the Bayesian least-squares method.
Watanabe M; Fukuoka N; Takeuchi T; Yamaguchi K; Motoki T; Tanaka H; Kosaka S; Houchi H
Biol Pharm Bull; 2014; 37(6):916-21. PubMed ID: 24882404
[TBL] [Abstract][Full Text] [Related]
29. Bayesian optimal designs for pharmacokinetic models: sensitivity to uncertainty.
Dokoumetzidis A; Aarons L
J Biopharm Stat; 2007; 17(5):851-67. PubMed ID: 17885870
[TBL] [Abstract][Full Text] [Related]
30. Developments of inverse analysis by Kalman filters and Bayesian methods applied to geotechnical engineering.
Murakami A; Fujisawa K; Shuku T
Proc Jpn Acad Ser B Phys Biol Sci; 2023; 99(9):352-388. PubMed ID: 37952976
[TBL] [Abstract][Full Text] [Related]
31. Efficient estimation and prediction for the Bayesian binary spatial model with flexible link functions.
Roy V; Evangelou E; Zhu Z
Biometrics; 2016 Mar; 72(1):289-98. PubMed ID: 26331903
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of Bayesian estimation of pharmacokinetic parameters.
Tsuchiwata S; Mihara K; Yafune A; Ogata H
Ther Drug Monit; 2005 Feb; 27(1):18-24. PubMed ID: 15665741
[TBL] [Abstract][Full Text] [Related]
33. Parametric Bayesian filters for nonlinear stochastic dynamical systems: a survey.
Stano P; Lendek Z; Braaksma J; Babuska R; de Keizer C; den Dekker AJ
IEEE Trans Cybern; 2013 Dec; 43(6):1607-24. PubMed ID: 23757593
[TBL] [Abstract][Full Text] [Related]
34. Investigation of the prediction accuracy of vancomycin concentrations determined by patient-specific parameters as estimated by Bayesian analysis.
Hiraki Y; Onga T; Mizoguchi A; Tsuji Y
J Clin Pharm Ther; 2010 Oct; 35(5):527-32. PubMed ID: 20831677
[TBL] [Abstract][Full Text] [Related]
35. State estimation of stochastic non-linear hybrid dynamic system using an interacting multiple model algorithm.
Elenchezhiyan M; Prakash J
ISA Trans; 2015 Sep; 58():520-32. PubMed ID: 26303958
[TBL] [Abstract][Full Text] [Related]
36. Vancomycin dosing in children and young adults: back to the drawing board.
Camaione L; Elliott K; Mitchell-Van Steele A; Lomaestro B; Pai MP
Pharmacotherapy; 2013 Dec; 33(12):1278-87. PubMed ID: 24019205
[TBL] [Abstract][Full Text] [Related]
37. Bayesian phylogeny analysis via stochastic approximation Monte Carlo.
Cheon S; Liang F
Mol Phylogenet Evol; 2009 Nov; 53(2):394-403. PubMed ID: 19589389
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic Studies in Neonates: The Utility of an Opportunistic Sampling Design.
Leroux S; Turner MA; Guellec CB; Hill H; van den Anker JN; Kearns GL; Jacqz-Aigrain E; Zhao W;
Clin Pharmacokinet; 2015 Dec; 54(12):1273-85. PubMed ID: 26063050
[TBL] [Abstract][Full Text] [Related]
39. Pilot Study of a Bayesian Approach To Estimate Vancomycin Exposure in Obese Patients with Limited Pharmacokinetic Sampling.
Carreno JJ; Lomaestro B; Tietjan J; Lodise TP
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28289024
[TBL] [Abstract][Full Text] [Related]
40. A Bayesian Multinomial Probit MODEL FOR THE ANALYSIS OF PANEL CHOICE DATA.
Fong DK; Kim S; Chen Z; DeSarbo WS
Psychometrika; 2016 Mar; 81(1):161-83. PubMed ID: 25491165
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
